CircRNAs modulate response of cancer cells to gemcitabine
As a chemotherapeutic agent, gemcitabine makes the backbone of several chemotherapeutic regimens, particularly those used for advanced cancers. However, drug resistance confines the long-term therapeutic impact of gemcitabine in cancer treatment and makes the patients' prognosis poor. Several m...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-12-01
|
| Series: | Advances in Cancer Biology - Metastasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667394025000115 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | As a chemotherapeutic agent, gemcitabine makes the backbone of several chemotherapeutic regimens, particularly those used for advanced cancers. However, drug resistance confines the long-term therapeutic impact of gemcitabine in cancer treatment and makes the patients' prognosis poor. Several mechanisms such as alteration of membrane transporters, abnormal regulation of activating and inactivating enzymes, and alterations in signaling pathway have been proposed for induction of resistance to gemcitabine. However, none of them could individually explain the varied spectrum of patients' responses to this agent. Recent recognition of the role of circular RNAs (circRNAs) in the pathoetiology of cancer has opened a new venue for identification of molecular events leading to chemoresistance. The current review provides insights into the role of specific circRNAs in determination of response to gemcitabine. |
|---|---|
| ISSN: | 2667-3940 |